A new synthesis finds that common epilepsies are driven by thousands of tiny-effect genetic variants, most still ...

MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women's Hospital and an instructor of neurology at Harvard Medical ...

Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women’s Hospital and an instructor of neurology at Harvard Medical ...

“At present, there is insufficient evidence to inform clinical practice regarding clobazam monotherapy in focal or generalized seizures,” concluded the authors, adding “There is a definite need for ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

The International League Against Epilepsy (ILAE) has revised its classification of seizure types to improve nomenclature, add new seizure types, and give clinicians the ability to classify seizures ...

Patients with refractory partial and secondarily generalized seizures had a reduction in seizures after deep brain stimulation, according to new research. This multi-center clinical trial determined ...

Valproate (Depakene) emerged as the best first-line choice for generalized epilepsy in a pragmatic study and lamotrigine (Lamictal) as the best first-line treatment for focal epilepsy, British ...